Asia-Pacific Cancer Therapy Market
The Asia-Pacific market for cancer therapy was estimated at USD XXmillion for the year 2016 and is projected to reach USD XXmillion by the end of 2022 at a CAGR of XX % during the forecast period from 2017 to 2022.
According to the World Health Organization (WHO), more than 6 million new cancer cases are diagnosed in Asia every year. Cancer is the leading cause of death and the incidence rates are increasing annually. Due to this, the demand for quality cancer treatments has risen dramatically, which is contributing to the growth of the market.
The end-users of this market are clinics, hospitals, and research centers. Lung cancer, breast cancer, colorectal cancer, ovarian cancer, head & neck cancer, stomach cancer and liver cancer are some of the common cancers increasing the treatment options in Asia.
Increasing incidence of cancer
Growing demand for advanced therapies
Patent expiry of leading drugs
Increasing public awareness about diseases and treatment options
High prices of therapies
Side-effects caused during treatment
Change in reimbursement policies
The market for cancer therapy in Asia-Pacific is segmented based on the type of therapy, which includes chemotherapy (marketed drugs and drugs in the pipeline), radiotherapy, surgery, hormone therapy, targeted cancer therapy, immunotherapy (monoclonal antibodies, cancer vaccines, and non-specific immunotherapy) and combination therapy. Chemotherapy, radiation therapy, and combinational therapy are increasingly available in the Asia-Pacific region. However, chemotherapy is the largest segment of APAC cancer therapeutics market. Based on geography, Asia Pacific market is segmented into China, India, Japan, Australia, South Korea and Rest of APAC.
Many players in this market are trying to expand their product portfolio in order to top the global market. While a few companies are entering the market by acquisitions, top companies are expanding their growth by acquiring other companies. Some companies have adopted product innovation and new product launches as their key business strategy to ensure their dominance in this market. Roche is developing a large number of combinational therapies.
Some of the key players in this market include –
AstraZeneca, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Pfizer, Teva and others.
Market analysis for the Asia-Pacific cancer therapy market, with region-specific assessments and competition analysis on the global and regional scale.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market share.
Identification and analysis of the macro and micro factors that affect the Asia-Pacific cancer therapy market on both global and regional scale.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is growing and to also identify the regions that are still untapped.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porters Five Forces
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Market Drivers, Restraints, Opportunities and Challenges (DROC) Analysis
6.1 Market Drivers
6.1.1 Rise in Cancer Incidence and Access to Modern Therapeutics
6.1.2 Increasing Aging Population
6.1.3 Innovations, Improvements and Approvals
6.2 Market Restraints
6.2.1 High Price of Therapy
6.2.2 Change in Reimbursement Policies
6.2.3 Challenges Encountered In Clinical Trials
6.3 Market Challenges
6.4 Market Opportunities
7. Market Segmentation
7.1 Market Segmentation by Types of Cancer
7.1.1 Blood Cancer
7.1.2 Bone Cancer
7.1.3 Brain Cancer
7.1.4 Breast Cancer
7.1.5 Digestive/ Gastrointestinal Cancer
7.1.6 Endocrine Cancer
7.1.7 Eye Cancer
7.1.8 Genitourinary Cancer
7.1.9 Gynecologic Cancer
7.1.10 Head & Neck Cancers
7.1.11 Respiratory/Lung Cancer
7.1.12 Skin Cancer
7.2 Market Segmentation by Cancer Treatment Types
7.2.3 Radiation Therapy
7.2.4 Targeted Therapy
7.2.5 Immunotherapy (Biologic Therapy)
7.2.6 Hormonal Therapy
7.2.8 Stem Cell Transplant
7.2.9 Signal Transduction Inhibitors
7.2.10 Gene Expression Modulators
7.2.11 Apoptosis Inducers
7.2.12 Angiogenesis Inhibitors
7.2.13 Other Therapy
7.3 Market Segmentation by Target Therapy
7.3.1 Targeted Cancer Therapeutics
22.214.171.124 Targeted Cancer Therapy vs. Chemotherapy
126.96.36.199 Targets for Targeted Cancer Therapy
188.8.131.52 Types of Targeted Cancer Therapy
7.3.2 Hormone Therapy
184.108.40.206 Monoclonal Antibodies
220.127.116.11.1 Naked Monoclonal Antibodies
18.104.22.168.2 Conjugated Monoclonal Antibodies
22.214.171.124.2.1 Radiolabeled Antibodies
126.96.36.199.2.2 Chemolabeled Antibodies
7.4 Market Segmentation by Cancer Vaccines
7.4.1 Vaccines to Help Prevent Cancer
7.4.2 Vaccines to Help Treat Cancer
7.4.3 Non-Specific Immunotherapy
7.5 Market Segmentation by Aromatase Inhibitors
7.5.1 Estrogen Receptors down Regulators
7.5.2 Hormone Therapy vs. HRT
7.6 Market Segmentation by Type of Applications
7.6.1 Nasal Spray
7.6.2 Pills or Tablets, Taken By Mouth
7.6.3 Skin Gel
7.6.4 Skin Patches
7.6.5 Vaginal Creams or Vaginal Tablets
7.6.6 Vaginal Ring
7.7 Market Segmentation by Types of Agents
7.7.1 Alkylating Agents
7.7.3 Anti-Microtubule Agents
7.7.4 Topoisomerase Inhibitors
7.7.5 Cytotoxic Antibiotics
7.8 Market Segmentation by Types of Chemotherapy Regimens
7.8.1 Breast Cancer
7.8.3 Germ Cell Tumor
7.8.4 Stomach Cancer
7.8.5 Bladder Cancer
7.8.6 Lung Cancer
8. Market Segmentation by Geography
8.1 Asia-Pacific (APAC)
8.1.5 South Korea
8.1.6 Rest of Asia-Pacific
9. Company Profiles
9.1 Astrazeneca Plc
9.2 Chugai Pharmaceutical Co., Ltd.
9.3 Genentech Inc.
9.4 Glaxosmithkline Plc
9.5 GPC Biotech Ag
9.6 OSI Pharmaceuticals, Inc.
10. Future Outlook of the Market